epatocellular carcinoma (HCC) is the most common type of primary liver cancer. Advanced HCC has poor prognosis with short survival rate. According to Barcelona Classification of Liver Cancer (BCLC), systemic therapy is optimal treatment for patients at this stage. In 2007, the targeted therapy with sorafenib was first approved to treat advanced HCC, which helps prolong survival of the patients. This article aims: To update the findings and application of adjuvant regimens for HCC. |
